Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call
Rhea-AI Summary
Fortrea (Nasdaq: FTRE) will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
The company will host a conference call at 8:00 am ET the same day with a Q&A. Participants should register on the Fortrea Investor Relations website, join at least 10 minutes early, and can access a live webcast. A replay will be posted in the events and presentations section.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, FTRE gained 1.91%, reflecting a mild positive market reaction. This price movement added approximately $30M to the company's valuation, bringing the market cap to $1.58B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FTRE fell 2.28% with several peers also down (e.g., MRVI -10%, EYPT -4.87%, QURE -4.24%), but no broad sector momentum flag was triggered.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 09 | Conference timing update | Neutral | -0.3% | Updated J.P. Morgan Healthcare Conference presentation time and webcast details. |
| Jan 06 | Conference presentation | Positive | +5.5% | Announcement of participation and presentation at J.P. Morgan Healthcare Conference. |
| Dec 10 | Inducement equity awards | Neutral | +5.2% | Grant of 245,000 RSUs to new hires under inducement award plan. |
| Dec 04 | Strategic collaboration | Positive | -0.7% | Strategic collaboration with SCTbio to align CDMO manufacturing and CRO services. |
| Nov 25 | Conference participation | Positive | +7.0% | Participation in Citi and Evercore healthcare conferences with webcast access. |
Recent stock reactions to corporate news and conference-related updates have mostly been positive, with one notable divergence on a strategic collaboration announcement.
Over the past few months, Fortrea has focused on investor outreach and strategic positioning. Updates on conference participation and presentation timings in November 2025 and January 2026 often coincided with positive single-day moves, while a strategic collaboration on December 4, 2025 saw a small negative reaction. Inducement RSU grants on December 10, 2025 also preceded a positive move. Today’s earnings date announcement fits within this pattern of informational updates to the investment community.
Market Pulse Summary
This announcement sets the timetable for Fortrea’s Q4 and full-year 2025 earnings release and conference call on February 26, 2026 at 8:00 am ET. It signals the next key checkpoint for updated revenue, profitability, and cash-flow trends following the last reported quarter. In the interim, investors may focus on existing regulatory filings, prior earnings performance, and operational updates to frame expectations for the upcoming results and any accompanying outlook commentary.
Key Terms
contract research organization (CRO) medical
AI-generated analysis. Not financial advice.
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.
To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.
A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea Investor Relations website.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts
Tracy Krumme (Investors) – 984-385-6707, tracy.krumme@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com
Kate Dillon (Media) – 646-818-9115, kdillon@prosek.com
FAQ
When will Fortrea (FTRE) release its Q4 and full year 2025 results?
What time is the Fortrea (FTRE) earnings conference call on February 26, 2026?
How can investors participate in the Fortrea (FTRE) Q4 2025 earnings call?
Will Fortrea (FTRE) provide a replay of the February 26, 2026 earnings call?
Where can I find the Fortrea (FTRE) webcast and supporting materials for Q4 2025?
